All In Biotech

Drug Trial Radar · NCT03451851

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (>=6 To <18 Years of Age)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Actual

Start

Jul 11, 2018

Primary completion

Jul 19, 2023

Study completion Dec 18, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • GuselkumabDrug

    Participants will receive a weight-based dose of guselkumab subcutaneously.

  • Placebo for guselkumabDrug

    Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.

  • EtanerceptDrug

    Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16Time frame: At Week 16
  2. Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16Time frame: At Week 16

Locations

39 sites in 9 countries. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • University of California, San Diego

    San Diego, California

  • Dermatologic Surgery Specialists

    Macon, Georgia

  • Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital

    Chicago, Illinois

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • Windsor Dermatology

    East Windsor, New Jersey

  • Mt. Sinai School of Medicine

    New York, New York

  • Wright State Physicians Health Center

    Dayton, Ohio

  • Arlington Center for Dermatology

    Arlington, Texas

  • Dell Children's Medical Center of Central Texas

    Austin, Texas

  • Eastern Health Research

    Box Hill, Australia

  • Royal North Shore Hospital

    St Leonards, Australia

  • Veracity Clinical Research

    Woolloongabba, Australia

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • Kirk Barber Reseach Inc.

    Calgary, Alberta, Canada

  • Dermatology Research Institute Inc

    Calgary, Alberta, Canada

  • Skin Care Centre

    Vancouver, British Columbia, Canada

  • Universitatsklinikum Bonn

    Bonn, Germany

  • Universitatsklinikum Carl Gustav Carcus Dresden

    Dresden, Germany

  • Universitatsklinikum Frankfurt

    Frankfurt, Germany

  • Universitatsklinikum Schleswig Holstein Kiel

    Kiel, Germany

  • Praxis Dr. med. Beate Schwarz - Germany

    Langenau, Germany

  • Company for Medical Study & Service Selters

    Selters, Germany

  • Hautarztpraxis Dr. Leitz & Kollegen

    Stuttgart, Germany

  • Obudai Egeszsegugyi Centrum Kft

    Budapest, Hungary

  • Debreceni Egyetem

    Debrecen, Hungary

  • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz

    Miskolc, Hungary

  • Szegedi Tudomanyegyetem

    Szeged, Hungary

  • Ospedali Riuniti Di Ancona

    Ancona, Italy

  • Azienda Ospedaliera Policlinico S. Orsola-Malpighi

    Bologna, Italy

  • AOU di Cagliari

    Cagliari, Italy

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • Arcispedale Santa Maria Nuova - IRCCS

    Reggio Emilia, Italy

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Dermed Centrum Medyczne Sp z o o

    Lodz, Poland

  • Szpital Dzieciecy im. prof. dr. med. Jana Bogdanowicza w Warszawie

    Warsaw, Poland

  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.